Prediction of chemotherapy response in untreated malignant lymphomas using technetium-99m methoxyisobutylisonitrile scan: Comparison with P-glycoprotein expression and other prognostic factors. A preliminary report

Japanese Journal of Clinical Oncology

Volumn 32, Issue 4, 2002, Pages 140-145

  Liang, Ji An ^a   Shiau, Yu Chien ^b   Yang, Shih Neng ^a   Lin, Fang Jen ^a,c   Kao, Albert ^a   Lee, Cheng Chun ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Chemotherapy response; Lymphoma; P glycoprotein expression; Technetium 99m methoxyisobutylisonitrile

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; GALLIUM CITRATE GA 67; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PERCHLORATE; PERTECHNETIC ACID TC 99M; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG UPTAKE; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR BIOPSY; BIOSYNTHESIS; COMPARATIVE STUDY; LEUKEMIA; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; FEMALE; HUMANS; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0036526837     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyf027     Document Type: Article

References (24)

1. Barr L, Cowan R, Nicolson M. Haematological malignancies. In: Barr L, Cowan R, Nicolson M, editors. Oncology. New York: Churchill Livingstone 1997;150-5.
2. Neal AJ, Hoskin PJ. Lymphoma. In: Neal AJ, Hoskin PJ, editors. Clinical Oncology: Basic Principle and Practice, 2nd ed. London: Arnold 1997;162-74.
3. Wilson WH, Chabner BA. Principles of chemotherapy for lymphomas. In: Canellos GP, Lister TA, Sklar JL, editors. The Lymphomas, 1st ed. Philadelphia: Saunders 1998;235-45.
4. Marie JP. P-glycoprotein in adult hematologic malignancies. Hematol Oncol Clin N Am 1995;9:239-49.
5. Niehans GA, Jaszcz W, Brunetto V, Perri RT, Gajl-Peczalska K, Wick MR, et al. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 1992;52:3768-75.
6. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-gtycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989;7:415-24.
7. Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995;76:2351-6.
8. Zhan Z, Sandor VA, Gamelin E, Regis J, Dickstein B, Wilson W, et al. Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay. Blood 1997;89:3795-800.
9. Kao CH, Tsai SC, Wang JJ, Ho YJ, Ho ST, Changlai SP. Technetium-99m- sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factors. Br J Haematol 2001;113:369-74.
10. Kapucu LO, Akyuz C, Vural G, Oguz A, Atasever T, Buyukpamukcu M, et al. Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi. J Nucl Med 1997;38:243-7.
11. Kostakoglu L, Guc D, Canpinar H, Kars A, Alper E, Kiratli P, et al. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy. J Nucl Med 1998;39:1191-7.
12. Kostakoglu L, Elahi N, Kiratli P, Ruacan S, Sayek I, Baltali E, et al. Clinical validation of the influence of P-glyocprotein on technetium-99m- sestamibi uptake in malignant tumors. J Nucl Med 1997;38:1003-8.
13. Shih WJ, Rastogi A, Stipp V, Magoun S, Coupal J. Functional retention of Tc-99m MIBI in mediastinal lymphomas as a predictor of chemotherapeutic response demonstrated by consecutive thoracic SPECT imaging. Clin Nucl Med 1998;23:505-8.
14. Hendrikse NH, Franssen EJ, van-der-Graaf WT, Vaalburg W, de-Vries EG. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999;26:283-93.
15. Hendrikse NH, Franssen EJ, van-der-Graaf WT, Meijer C, Piers DA, Vaalburg W, de-Vries EG. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 1998;77:353-8.
16. Kostakoglu L, Kiratli P, Ruacan S, Hayran M, Emri S, Ergun EL, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med 1998;39:228-34.
17. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-84.
18. Sun SS, Hsieh JF, Tsai SC, Ho YJ, Lee JK, Kao CH. Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results. Cancer Lett 2000;153:95-100.
19. Vergote J, Moretti JL, de-Vries EG, Garnier-Suillerot A. Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-gtycoprotein- mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. Eur J Biochem 1998;252:140-6.
20. Jaffe ES. Histopathology of the non-Hodgkin's lymphomas and Hodgkin's disease. In: Canellos GP, Lister TA, Sklar JL, editors. The Lymphomas, 1 ed. Philadelphia: Saunders 1998;77-106.
21. Sun SS, Tsai SC, Wang JJ, Ho YJ, Ho ST, Kao CH. Technetium-99m- tetrofosmin scintigraphy in the prediction of chemotherapy response of untreated malignant lymphomas and comparison with other prognostic factors. Anticancer Res 2001;21:685-8.
22. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis(2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblast. J Nucl Med 1990;31:1646-53.
23. Kao CH, Changlai SP, Chieng PU, Yen TC. Technetium-99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma. Relationship to patient prognosis and chemotherapy response - a preliminary report. Cancer 1998;83:64-8.
24. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Lee JK. Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photonemission computed tomography. Clin Cancer Res 2000;6:820-4.